Please assess the completion status of the following clinical trial:

Trial Title: Early Prophylaxis Immunologic Challenge (EPIC) Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with severe and moderately severe hemophilia A (FVIII ≤ 2%)~* Participants \< 1 year of age~* Participants must have ≤ 3 exposure days (EDs) to any FVIII concentrate or FVIII-containing product used for treatment of minor bleeds (bleeds requiring no more than 2 infusions per event), or for preventative or precautionary infusions following possible injury~* Participants with prior circumcision are allowed to enroll only if bleeding issues related to circumcision were the cause for the original diagnosis of hemophilia A and no more than 2 EDs of FVIII treatment were required~* Adequate venous access (without need for central venous access device (CVAD)-placement) as determined by the physician~* Written informed consent from legally authorized representative(s)~Exclusion Criteria:~* Life-threatening conditions (intracranial hemorrhage, severe trauma) or requirement for surgery at the time of enrollment~* Evidence of inhibitor ≥ 0.6 Bethesda Unit (BU) in Nijmegen-modified Bethesda Assay at study start (samples may be retested using lupus-insensitive inhibitor tests to reduce the number of false positive inhibitor test results)~* Inherited or acquired hemostatic defect other than hemophilia A~* Any clinically significant, chronic disease other than hemophilia A~* Known hypersensitivity to ADVATE or any of its constituents~* Any planned elective surgery that cannot be postponed until after the first 20 EDs~* Participation in the Hemophilia Inhibitor Previously Untreated Patient Study~* Application of red blood cell, platelet, or leukocyte concentrates, or plasma~* Administration of any medication affecting coagulation or platelet function~* Systemic administration of any immunomodulatory drug (eg, chemotherapy, intravenous glucocorticoids)~* Participation in another clinical study involving an investigational product (IP) or device within 30 days prior to study enrollment or during the course of this study

- Gender: MALE
- Minimum Age: None
- Maximum Age: 1 Year
- Healthy Volunteers: f

Study Arms:
- ADVATE - Prophylactic Regimen (Type: EXPERIMENTAL): Weekly infusions of ADVATE. Study visits (physical examination, lab tests including FVIII inhibitor tests) every week during the first 10 exposure days (EDs), every 5 weeks during the next 10 EDs and every 10 weeks thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).